Impact of a social marketing media campaign on public awareness of hypertension

American Journal of Hypertension

Volumn 18, Issue 2, 2005, Pages 270-275

  Petrella, Robert J ^a,d   Speechley, Mark ^a   Kleinstiver, Peter W ^b   Ruddy, Terry ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Katalyst Health Technology Assessments   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d Can Coal High Blood Pressure P   (Canada)

Author keywords

Awareness; Hypertension; Mass media; Social marketing

Indexed keywords

BLOOD PRESSURE; CANADA; FEMALE; HEALTH BEHAVIOR; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH PROMOTION; HEALTH SURVEY; HUMAN; HYPERTENSION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MASS MEDIUM; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 14744302930     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2004.09.012     Document Type: Article

References (23)

1. M.R. Joffres, P. Ghadirian, J.G. Fodor, A. Petrasovits, A. Chocklingam, P. Hamet Awareness, treatment, and control of hypertension in Canada Am J Hypertens 10 1997 1097 1102
2. K.B. Zarnke, N.R.C. Campbell, F. McAlister, M. Levine Canadian Hypertension Recommendations Working Group A novel process for updating recommendations for updating recommendations for managing hypertension rationale and methods Can J Cardiol 16 2000 1094 1102
3. F.A. McAllister, N.R.C. Campbell, K. Zarnke, M. Levine, I.D. Graham The management of hypertension in Canada a review of current guidelines, their shortcomings and implications for the future CMAJ 164 2001 517 522
4. L.M.H. Wing, C.M. Reid, P. Ryan, L.J. Beilin, M.A. Brown, G.L.R. Jennings Second Australian National Blood Pressure Study Group A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly N Engl J Med 348 2003 583 592
5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs. diuretic The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
6. B. Dahlof, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. Faire The Life Study Group Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol Lancet 359 2002 995 1003
7. L.J. Appel, C.M. Champagne, D.W. Harsha, L.S. Copper, E. Obarzanek, P.J. Elmer Writing Group of the PREMIER Collaboration Research Group Effects of comprehensive lifestyle modification on blood pressure control main results of the PREMIER clinical trial JAMA 289 2003 2083 2093
8. T.J. Moore, W.M. Vollmer, L.J. Appel, F.M. Sacks, L.P. Svetkey, T.M. Vogt, P.R. Conlin, D.G. Simons-Morton, L. Carter-Edwards, D.W. Harsha Effect of dietary patterns on ambulatory blood pressure results from the Dietary Approaches to Stop Hypertension (DASH) Trial DASH Collaborative Research Group. Hypertension 34 1999 472 477
9. A.V. Chobanian Control of hypertension--an important national priority N Engl J Med 345 2001 534 535
10. M.R. Joffres, P. Hamet, D.R. MacLean, G.J. L'italien, G. Fodor Distribution of blood pressure and hypertension in Canada and the United States Am J Hypertens 14 2001 1099 1105
11. D.R. Berlowitz, A.S. Ash, E.C. Hickey, R.H. Friedman, M. Glickman, B. Kader, M.A. Moskowitz Inadequate management of blood pressure in a hypertensive population N Engl J Med 319 1998 1957 1963
12. K. Wolf-Maier, R.S. Cooper, H.W. Hense, J.R. Banegan, S. Gianpaoli, M.R. Joffres, M. Kastarinen, N. Poulter, P. Primatesta, F. Rodriguez-Artalejo, M. Thamm, J. Tuomilehto, D. Vanizzo, F. Vescio Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States JAMA 289 2003 2363 2368
13. S.A. Kirkland, D.R. MacLean, D.B. Langille, M.R. Joffres, K.M. MacPherson, P. Andreou Knowledge and awareness of risk factors for cardiovascular disease among Canadians 55 to 74 years of age; results from the Canadian Heart Health Surveys, 1986-1992 CMAJ 161 8 Suppl 1999 S10 S16
14. N.E. Avis, J.B. McKinley, K.W. Smith Is cardiovascular risk factor knowledge sufficient to influence behavior? Am J Prev Med 6 1990 137 144
15. S.K. Davis, M.A. Winkleby, J.W. Farquhar Increasing disparity in knowledge of CVD risk factors and risk-reduction strategies by socio-economic status implications for policymakers Am J Prev Med 11 1995 318 323
16. M. Poscente, M. Rothstein, M.J. Irvine Using market research methods to evaluate a stage-specific intervention Am J Health Behav 26 2002 243 251
17. S.P. David, D.S. Greer Social marketing application to medical education Ann Intern Med 34 2001 125 127
18. S.J. Pocock Clinical Trials A Practical Approach 1982 John Wiley & Sons Chicester, England
19. R.S. Vassan, A. Beiser, S. Seshadri, M.G. Larson, W.B. Kannel, R.B. D'Agostino, D. Levy Residual lifetime risk for development of hypertension in middle-aged men and women. The Framingham Heart Study JAMA 287 2002 1003 1010
20. A. Chockalingam, N. Campbell, T. Ruddy, G. Taylor, P. Stewart, R. Petrella Canadian national high blood pressure prevention and control strategy Can J Cardiol 16 2000 1087 1093
21. T. Karvonen, A. Uutela, H.J. Korhonen, P. Puska Impact of mass media and interpersonal health communication on smoking cessation attempts a study in North Karelia, 1989-1996 J Health Commun 3 1998 105 118
22. K. Friend, D.T. Levy Reductions in smoking prevalence and cigarette consumption associated with mass- media campaigns Health Educ Res 17 2002 85 98
23. C.P. Herbert Should physicians assess lifestyle risk factors routinely? CMAJ 160 1999 1849 1850